# AZTherapies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aztherapies

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.aztherapies.com
- Total disclosed funding: $45M
- Latest round: Series C (Sep 29, 2020)
- Investors on record: 10

## About

Founded in 2011 and based in Massachusetts, US, AZTherapies Inc. operates as a  biotechnology company that develops pharmaceutical drugs used for multiple neurodegenerations and neuroinflammation-related CNS diseases. The company's platform also develops ALZT-OP1, a combined oral-inhaled therapy to slow down the progression of early Alzheimer’s disease.

## Funding rounds

- Series C, Sep 29, 2020, $15M — Wexford Capital, DEFTA Partners, Spinnaker Capital, Duopharma Biotech Berhad, ID Fund, DRADS Capital
- Series C, Jan 1, 2020, $11M — ID Fund, Axiom Associates, KClavis Investment
- Series C, Jun 28, 2019, $19M — Wexford Capital, Spinnaker Capital, IBS Capital, The Cosine Group, DRADS Capital

## Investors

- Wexford Capital — Series C
- Spinnaker Capital (https://capitalatlas.ai/funds/spinnaker-capital) — Series C
- IBS Capital — Series C
- The Cosine Group — Series C
- DRADS Capital — Series C
- ID Fund (https://capitalatlas.ai/funds/id-fund) — Series C
- Axiom Associates — Series C
- KClavis Investment (https://capitalatlas.ai/funds/kclavis-investment) — Series C
- DEFTA Partners (https://capitalatlas.ai/funds/defta-partners) — Series C
- Duopharma Biotech Berhad — Series C